Literature DB >> 2776169

Measurement of quality-of-life changes in patients with Alzheimer's disease.

R DeJong1, O W Osterlund, G W Roy.   

Abstract

A scale was developed that appears to be a reliable and sensitive indicator of differences and changes in the quality of life of patients with Alzheimer's disease (AD) as the disease progresses. The instrument was generated from interviews with spouses and/or caregivers of AD patients, and was designed to be completed easily by the caregiver. The bipolar analog scale was based on the daily behavior of AD patients and was developed in three steps involving interviews with caregivers (step I), testing of questionnaires, and validation of the instrument. At step II, four iterative trials, each with a different version of the questionnaire, were performed for validation. The final form of the Progressive Deterioration Scale (PDS) contained 27 quality-of-life factors and was cross-validated in a second, separate study. The Global Deterioration Scale (GDS) for cognitive function was used as the external criterion for the analysis of the quality-of-life scales. Statistical analysis indicates that the PDS provides a reliable, valid, and sensitive measure of changes in the quality of life as AD progresses. The PDS achieved 80% overall accuracy in discriminating non-AD elderly patients from patients in the early, middle, and late stages of AD. This scale may provide a useful means for clinical evaluation (phase III) of potential medications to alleviate the symptoms of AD.

Entities:  

Mesh:

Year:  1989        PMID: 2776169

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  42 in total

Review 1.  Acetylcholinesterase inhibitors in Alzheimer's disease.

Authors:  B M McGleenon; K B Dynan; A P Passmore
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

2.  Effectiveness of rivastigmine in Alzheimer's disease. Improvements in functional ability remain unestablished.

Authors:  P Bentham; R Gray; E Sellwood; J Raftery
Journal:  BMJ       Date:  1999-09-04

Review 3.  The cost of Alzheimer's disease. Will drug treatment ease the burden?

Authors:  W Max
Journal:  Pharmacoeconomics       Date:  1996-01       Impact factor: 4.981

Review 4.  Long-term cholinesterase inhibitor treatment of Alzheimer's disease.

Authors:  Peter Johannsen
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 5.  Rivastigmine from capsules to patch: therapeutic advances in the management of Alzheimer's disease and Parkinson's disease dementia.

Authors:  Carl H Sadowsky; Joseph L Micca; George T Grossberg; Drew M Velting
Journal:  Prim Care Companion CNS Disord       Date:  2014-09-04

6.  How are quality of life ratings made? Toward a model of quality of life in people with dementia.

Authors:  L M T Byrne-Davis; P D Bennett; G K Wilcock
Journal:  Qual Life Res       Date:  2006-06       Impact factor: 4.147

Review 7.  Drug treatment of Alzheimer's disease. Effects on caregiver burden and patient quality of life.

Authors:  L Hollister; N Gruber
Journal:  Drugs Aging       Date:  1996-01       Impact factor: 3.923

Review 8.  Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.

Authors:  Michael W Jann; Kara L Shirley; Gary W Small
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

9.  Update on the pharmacological treatment of Alzheimer's disease.

Authors:  Fadi Massoud; Serge Gauthier
Journal:  Curr Neuropharmacol       Date:  2010-03       Impact factor: 7.363

Review 10.  Effects of Ginkgo biloba in dementia: systematic review and meta-analysis.

Authors:  Stefan Weinmann; Stephanie Roll; Christoph Schwarzbach; Christoph Vauth; Stefan N Willich
Journal:  BMC Geriatr       Date:  2010-03-17       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.